There are a few suggestions for improvement that I am sure you will have no problem dealing with. We would thus be pleased to consider a revised submission, incorporating the reviewers' suggestions. I will be making an editorial decision on your next, final version.
Thank you again for the submission of your Review article manuscript to EMBO Molecular Medicine. We have now heard back from the three Reviewers whom we asked to evaluate your manuscript.
You will see that all three Reviewers are quite positive and agree that your manuscript is relevant, interesting, useful and well written.
There are a few suggestions for improvement that I am sure you will have no problem dealing with. We would thus be pleased to consider a revised submission, incorporating the reviewers' suggestions. I will be making an editorial decision on your next, final version.
In the likely event of acceptance, you will be asked to fulfill a number of editorial requirements as listed below. I suggest that you provide the following information and amendments requested with the next, final version of your manuscript to accelerate the process: 1) As per our Author Guidelines, the description of all reported data that includes statistical testing must state the name of the statistical test used to generate error bars and P values, the number (n) of independent experiments underlying each data point (not replicate measures of one sample), and the actual P value for each test (not merely 'significant' or 'P < 0.05'). Yopu may provide the P values as a separate table.
2) Every published paper now includes a 'Synopsis' to further enhance discoverability. Synopses are displayed on the journal webpage and are freely accessible to all readers. They include a short standfirst as well as 2-5 one sentence bullet points that summarise the paper. Please provide the synopsis including the short list of bullet points that summarise the key NEW findings. The bullet points should be designed to be complementary to the abstract -i.e. not repeat the same text. We encourage inclusion of key acronyms and quantitative information. Please use the passive voice. Please attach this information in a separate file or send them by email, we will incorporate it accordingly. You are also welcome to suggest a striking image or visual abstract to illustrate your article. If you do please provide a jpeg file 550 px-wide x 400-px high.
3) Please note that we now mandate that all corresponding authors list an ORCID digital identifier. You may do so though our web platform upon submission and the procedure takes <90 seconds to complete. We also encourage co-authors to supply an ORCID identifier, which will be linked to their name for unambiguous name identification.
I look forward to reading a new revised version of your manuscript as soon as possible. ***** Reviewer's comments ***** Referee #1 (Remarks):
Summary
The current manuscript by Goveia et al. provides a meta-analysis of clinical metabolic profiling (CMP) studies in tumor diseases and diabetes. In this respect, the authors compile CMP studies published between 2010 and 2015. They report that the vast majority of all published CMP studies only report on a subset of measured metabolites and also largely lack appropriate meta-data on patient tumor staging etc. Also, most CMP studies rely on a cross-sectional design, thereby not exploring a longitudinal change in metabolite levels during the course of the disease. In addition, the author's meta-analysis demonstrated that most data remain unconfirmed by independent experimental settings. Due to these limitations, the authors finally employed a semi-quantitative meta-analysis by vote-counting. These analyses demonstrated that across all included CMP studies a number of well-established tumor-associated metabolites, e.g. lactic acid and glutamic acid, could be confirmed to be enriched in tumor tissue. In addition, 3-hydroxbutyric acid could be identified a potential novel tumor marker in cancer patients. Overall, the authors conclude the there is a critical need for standardization across future CMP studies.
General Comments
Given the increasing recognition of tumor cell metabolism as a key feature of the malignant phenotype, the identification of tumor-associated metabolites and their potential role as biomarkers and/or therapeutic targets represents an important topic in oncology. In this regard, Goveia et al. provide an interesting and meaningful overview over the validity and usefulness of previously published CMP studies in the field. The manuscript is concise, clearly structured, and comes to clear statements regarding the potential impact of current CMP studies on clinical improvements in tumor diagnostics and therapies. Despite the fact that the chosen approach hardly allows for the discovery of novel metabolite pathways in cancer, the current manuscript may receive broad attention throughout the cancer metabolism community by raising awareness of the weaknesses and limitations of current clinical/experimental approaches. In this respect, the manuscript may serve as an "eye opener" for the cancer metabolite community to increase efforts in data harmonization and reproducibility.
Referee #2 (Remarks):
The manuscript represents an unorthodox and incisive effort to use metabolomic data for metaanalysis. A large portion of the work is a critique of the suitability of the published metabolomic literature for data mining. The authors cognetly discuss the limitations of the published literature for this purpose, and make an important comparison to genomic and epigenomic literature. The authors then seek to get around these limitations using a "vote-counting" method. This methods allows the authors to identify metabolites that are conistently enriched or depeleted in either tumor tissue or blood from cancer patients, compared to appropriate controls. With this method, the authors identify lactate and glutamate as enriched in tumors and glutamate and 3-hydroxybutyrate as enriched in the blood of cancer patients where tryptophan and glutamine are depleted. While these data are not highly novel, their finding demosntrates the potential of metabolomic meta-analysis, which will be realized more fully when critiques such as this are more widely appreciated.
Issues to be addressed : 1.The statistical methods are sound, but they are reported only in the Supplement. If these methods could be reported in the main text, it would enhance the paper.
2. The finding of increased lactate is expected and may reasonably be considered to validate the methods. However, the widespread acceptance of the phenomenon of aerobic glycolysis in cancer (which is an acceptance based on strong evidence) may be a source of bias. Studies finding increased lactate may be more likely to be reported or more likely to be published. Studies finding no change in lactate may be less likely to reach the published literature. This source of bias is inherent in meta-analysis and must be discussed.
3. The authors should discuss the possibility that 3-hydroxybutyrate may be elevated in cancer patients due to cachexia.
4. The authors should consider discussing that metabolomic studies are performed with a broader array of technologies than other holistic, non-biased approaches such as transcriptomics. While transcriptomic studies typically rely on either microarray and RNA-seq, metabolomic studies may use a wider variety of analytic methods, complicating direct comparisons between studies.
Referee #3 (Remarks):
This paper by Goveia and coll. entitled "Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities" reports a data mining and semi-quantitative meta-analysis of metabolites comparing healthy and cancer or diabetic patients, to identify distinct metabolite signatures in different pathologies. This study provides the evaluation of the feasibility of this kind of approach and gives some recommendations to improve its clinical impact. This paper is well written and reports important conclusions of clinical importance. Therefore, this work deserves publication in EMM.
Minor issue: Page 6 lines4-5: the sentence "Surprisingly, ... metabolites" is unclear. Please reformulate. 
REFEREE #1

Summary
General Comments
Given the increasing recognition of tumor cell metabolism as a key feature of the malignant phenotype, the identification of tumor-associated metabolites and their potential role as biomarkers and/or therapeutic targets represents an important topic in oncology. In this regard, Goveia et al.
provide an interesting and meaningful overview over the validity and usefulness of previously published CMP studies in the field. The manuscript is concise, clearly structured, and comes to clear statements regarding the potential impact of current CMP studies on clinical improvements in tumor diagnostics and therapies. Despite the fact that the chosen approach hardly allows for the discovery of novel metabolite pathways in cancer, the current manuscript may receive broad attention throughout the cancer metabolism community by raising awareness of the weaknesses and limitations of current clinical/experimental approaches. In this respect, the manuscript may serve as an "eye opener" for the cancer metabolite community to increase efforts in data harmonization and reproducibility.
GENERAL RESPONSE:
We thank referee #1 for these thoughtful comments assessing our metaanalysis as a valuable contribution to the field of cancer metabolism.
REFEREE #2
GENERAL RESPONSE:
We thank referee #2 for these generally positive comments. We appreciate the comment to report the statistical methods in the main text, which we originally included in the supplement due to space limitations. We also adapted the discussion as suggested and as detailed below. All changes to the text are marked in red.
Issues to be addressed :
1. The statistical methods are sound, but they are reported only in the Supplement. If these methods could be reported in the main text, it would enhance the paper.
RESPONSE:
The statistical methods are now presented in the main text (materials and methods section) (not marked in red).
2. The finding of increased lactate is expected and may reasonably be considered to validate the methods. However, the widespread acceptance of the phenomenon of aerobic glycolysis in cancer (which is an acceptance based on strong evidence) may be a source of bias. Studies finding increased lactate may be more likely to be reported or more likely to be published. Studies finding no change in lactate may be less likely to reach the published literature. This source of bias is inherent in meta-analysis and must be discussed. Is there an estimate of variation within each group of data?
Is the variance similar between the groups that are being statistically compared?
Yes, and we now moved full description of our statistical analyses from the supplements to the results section of the main text as suggested by the reviewers.
We use have used parametric (binomial test) and non--parametric (permutation--based) tests to assess statistical significance. The difference between the two procedures was neglectable, thus confirming that the data meet the distributional assumptions of the parametric test.
Within--group analysis of variance is not applicable in vote--counting 1. Data the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified Please fill out these boxes  (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
C--Reagents
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation. a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
